Get the Stockscreener App
6.77
0.59%
0.04
After Hours:
6.69
-0.08
-1.18%
Ocular Therapeutix Inc Stock (OCUL) Latest News
Does Ocular Therapeutix (NASDAQ:OCUL) Have A Healthy Balance Sheet? - Simply Wall St
Ocular Therapeutix™ to Present at Two Investor Conferences in March - The Manila Times
When Will Ocular Therapeutix Reveal Its Next Strategic Moves? CEO Set for Two Major Healthcare Conferences - StockTitan
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025 - The Manila Times
Ocular Therapeutix, Inc. Announces Conference Call to Discuss Q4 and Full Year 2024 Financial Results - Nasdaq
Legato Capital Management LLC Sells 34,695 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix CEO gets new compensation package - MSN
Ocular Therapeutix Approves New CEO Compensation Package - TipRanks
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives $17.00 Consensus Price Target from Brokerages - Defense World
Ocular Hypertension Clinical and Non-Clinical Studies, Key - openPR
How to Take Advantage of moves in (OCUL) - Stock Traders Daily
DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Donald Notman Sells 6,301 Shares - MarketBeat
The OCUL Stock Puzzle: Unraveling Ocular Therapeutix Inc’s Fluctuating Performance - The InvestChronicle
Analytical Overview: Ocular Therapeutix Inc (OCUL)’s Ratios Tell a Financial Story - The Dwinnex
Is Ocular Therapeutix Inc (OCUL) a good investment opportunity? - US Post News
Raymond James maintains $19 target on Ocular Therapeutix stock - MSN
Ocular Therapeutix Inc (OCUL) may enjoy gains as insiders got busy in the recent days - Knox Daily
Raymond James maintains $19 target on Ocular Therapeutix stock By Investing.com - Investing.com Canada
Ocular Therapeutix CFO Donald Notman sells $136,238 in stock By Investing.com - Investing.com Canada
Ocular Therapeutix CFO Donald Notman sells $136,238 in stock - Investing.com India
There is no way Ocular Therapeutix Inc (OCUL) can keep these numbers up - SETE News
Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) institutional investors lost 4.3% last week but have benefitted from longer-term gains - Simply Wall St
Ocular Therapeutix™ Announces Upcoming Presentations at the - GlobeNewswire
Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting - The Manila Times
Ocular Therapeutix, Inc. Announces Presentations at Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting - Nasdaq
Revolutionary Eye Treatment Data: Ocular's OTX-TKI Takes Center Stage at Premier Medical Conference - StockTitan
Ocular Therapeutix (NASDAQ:OCUL) Shares Cross Below 200 Day Moving AverageHere's What Happened - MarketBeat
SG Americas Securities LLC Buys 26,511 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix (NASDAQ:OCUL) Share Price Passes Below 200-Day Moving Average – Should You Sell? - Defense World
Advancements in Ocular Hypertension Clinical Trial Pipeline - GlobeNewswire
RoundAngle Advisors LLC Invests $1.70 Million in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) and Verona Pharma (NASDAQ:VRNA) Financial Contrast - Defense World
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ocular Therapeutix Grants Stock Options and RSU Awards to New Employee in Incentive Plan - StockTitan
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Ocular Therapeutix (STU:0OT) Cash From Discontinued Investi - GuruFocus.com
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR - GlobeNewswire
Ocular Therapeutix progresses with AXPAXLI trials for eye diseases By Investing.com - Investing.com Canada
Ocular Therapeutix progresses with AXPAXLI trials for eye diseases - Investing.com India
Ocular Therapeutix Advances AXPAXLI Eye Treatment Trials with Strong Enrollment Milestone - StockTitan
Neuropathic Ocular Pain Market Is Booming Worldwide 2025-2032 | - openPR
Investors push Ocular Therapeutix (NASDAQ:OCUL) 6.3% lower this week, company's increasing losses might be to blame - Simply Wall St
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):